Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98265 | 0.85 | DAO (0.37) | DAOIDO1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL4846564 | 0.79 | CES2 (0.34) | CES2CES1 | |
| SCHEMBL5543604 | 0.79 | TAAR1 (0.57) | DAOIDO1TAAR1 | |
| SCHEMBL15577862 | 0.79 | NOS1 (0.39) | CYP11B1 | |
| SCHEMBL5546168 | 0.76 | DAO (0.40) | DAOIDO1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL10546321 | 0.76 | MEN1 (0.52) | DAOIDO1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL980506 | 0.76 | TAAR1 (0.50) | DAOIDO1TAAR1 | |
| SCHEMBL21728102 | 0.76 | IDO1 (0.38) | DAOIDO1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL16105495 | 0.76 | IDO1 (0.50) | DAOIDO1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL4656516 | 0.75 | IDO1 (0.41) | DAOIDO1CES2CES1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | DAO 611/4885IDO1 647/4885CYP17A1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.